APO Research
Talk to an analyst

APO RESEARCH · REPORT

Topical Drugs CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Topical Drugs CDMO Market Outlook and Growth Opportunities 2026

30 December 2025194 pages

Choose your research edition.

Industry ResearchTopical Drugs CDMO Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Topical Drugs CDMO Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Topical Drugs CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Topical Drugs CDMO Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Topical Drugs CDMO Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Topical Drugs CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Topical Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Topical Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Topical Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Topical Drugs CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Topical Drugs CDMO market include Piramal Pharma Solutions, Pierre Fabre Group, PCI Pharma Services, MedPharm Ltd., Lubrizol Life Science, DPT Laboratories LTD., Contract Pharmaceuticals Limited, Cambrex Corporation and Bora Pharmaceutical CDMO, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Topical Drugs CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Topical Drugs CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Topical Drugs CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Topical Drugs CDMO market.

Topical Drugs CDMO Segment by Company

Piramal Pharma Solutions

Pierre Fabre Group

PCI Pharma Services

MedPharm Ltd.

Lubrizol Life Science

DPT Laboratories LTD.

Contract Pharmaceuticals Limited

Cambrex Corporation

Bora Pharmaceutical CDMO

Ascendia Pharmaceuticals

Topical Drugs CDMO Segment by Type

Contract Development

Contract Manufacturing

Topical Drugs CDMO Segment by Application

Semi-Solid Formulations

Solid Formulations

Liquid Formulations

Others

Topical Drugs CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Topical Drugs CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Topical Drugs CDMO key companies, revenue, market share, and recent developments.

3. To split the Topical Drugs CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Topical Drugs CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Topical Drugs CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Topical Drugs CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Topical Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Drugs CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Topical Drugs CDMO industry.

Chapter 3: Detailed analysis of Topical Drugs CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Topical Drugs CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Topical Drugs CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Topical Drugs CDMO Industry Trends Table 2. Topical Drugs CDMO Industry Drivers Table 3. Topical Drugs CDMO Industry Opportunities and Challenges Table 4. Topical Drugs CDMO Industry Restraints Table 5. Global Topical Drugs CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Topical Drugs CDMO Revenue Share by Company (2021-2026) Table 7. Global Topical Drugs CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Topical Drugs CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Topical Drugs CDMO Company, Product Type & Application Table 10. Global Topical Drugs CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Topical Drugs CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Contract Development Table 15. Significant Companies of Contract Manufacturing Table 16. Global Topical Drugs CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Topical Drugs CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Topical Drugs CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Topical Drugs CDMO Sales Value Share by Type (2021-2026) Table 20. Global Topical Drugs CDMO Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Semi-Solid Formulations Table 22. Significant Companies of Solid Formulations Table 23. Significant Companies of Liquid Formulations Table 24. Significant Companies of Others Table 25. Global Topical Drugs CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Topical Drugs CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Topical Drugs CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Topical Drugs CDMO Sales Value Share by Application (2021-2026) Table 29. Global Topical Drugs CDMO Sales Value Share by Application (2027-2032) Table 30. Global Topical Drugs CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Topical Drugs CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Topical Drugs CDMO Sales Value Share by Region (2021-2026) Table 33. Global Topical Drugs CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Topical Drugs CDMO Sales Value Share by Region (2027-2032) Table 35. Global Topical Drugs CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Topical Drugs CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Topical Drugs CDMO Sales Value Market Share by Country (2021-2026) Table 38. Global Topical Drugs CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Topical Drugs CDMO Sales Value Market Share by Country (2027-2032) Table 40. Piramal Pharma Solutions Company Information Table 41. Piramal Pharma Solutions Business Overview Table 42. Piramal Pharma Solutions Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio Table 44. Piramal Pharma Solutions Recent Development Table 45. Pierre Fabre Group Company Information Table 46. Pierre Fabre Group Business Overview Table 47. Pierre Fabre Group Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Pierre Fabre Group Topical Drugs CDMO Product Portfolio Table 49. Pierre Fabre Group Recent Development Table 50. PCI Pharma Services Company Information Table 51. PCI Pharma Services Business Overview Table 52. PCI Pharma Services Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. PCI Pharma Services Topical Drugs CDMO Product Portfolio Table 54. PCI Pharma Services Recent Development Table 55. MedPharm Ltd. Company Information Table 56. MedPharm Ltd. Business Overview Table 57. MedPharm Ltd. Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. MedPharm Ltd. Topical Drugs CDMO Product Portfolio Table 59. MedPharm Ltd. Recent Development Table 60. Lubrizol Life Science Company Information Table 61. Lubrizol Life Science Business Overview Table 62. Lubrizol Life Science Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Lubrizol Life Science Topical Drugs CDMO Product Portfolio Table 64. Lubrizol Life Science Recent Development Table 65. DPT Laboratories LTD. Company Information Table 66. DPT Laboratories LTD. Business Overview Table 67. DPT Laboratories LTD. Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio Table 69. DPT Laboratories LTD. Recent Development Table 70. Contract Pharmaceuticals Limited Company Information Table 71. Contract Pharmaceuticals Limited Business Overview Table 72. Contract Pharmaceuticals Limited Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio Table 74. Contract Pharmaceuticals Limited Recent Development Table 75. Cambrex Corporation Company Information Table 76. Cambrex Corporation Business Overview Table 77. Cambrex Corporation Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Cambrex Corporation Topical Drugs CDMO Product Portfolio Table 79. Cambrex Corporation Recent Development Table 80. Bora Pharmaceutical CDMO Company Information Table 81. Bora Pharmaceutical CDMO Business Overview Table 82. Bora Pharmaceutical CDMO Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio Table 84. Bora Pharmaceutical CDMO Recent Development Table 85. Ascendia Pharmaceuticals Company Information Table 86. Ascendia Pharmaceuticals Business Overview Table 87. Ascendia Pharmaceuticals Topical Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio Table 89. Ascendia Pharmaceuticals Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Topical Drugs CDMO Product Image Figure 2. Global Topical Drugs CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Topical Drugs CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Topical Drugs CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Contract Development Image Figure 8. Contract Manufacturing Image Figure 9. Global Topical Drugs CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Topical Drugs CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Topical Drugs CDMO Sales Value Share by Type (2021-2032) Figure 12. Semi-Solid Formulations Image Figure 13. Solid Formulations Image Figure 14. Liquid Formulations Image Figure 15. Others Image Figure 16. Global Topical Drugs CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Topical Drugs CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Topical Drugs CDMO Sales Value Share by Application (2021-2032) Figure 19. Global Topical Drugs CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Topical Drugs CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Topical Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 22. North America Topical Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Topical Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Topical Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Topical Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Topical Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Topical Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. South America Topical Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Topical Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Topical Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Topical Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Contract Development
  • Contract Manufacturing
Applications
  • Semi-Solid Formulations
  • Solid Formulations
  • Liquid Formulations
  • Others
Companies covered
  • Piramal Pharma Solutions
  • Pierre Fabre Group
  • PCI Pharma Services
  • MedPharm Ltd.
  • Lubrizol Life Science
  • DPT Laboratories LTD.
  • Contract Pharmaceuticals Limited
  • Cambrex Corporation
  • Bora Pharmaceutical CDMO
  • Ascendia Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Topical Drugs CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Topical Drugs CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Topical Drugs CDMO Market Dynamics
  1. 2.1 Topical Drugs CDMO Industry Trends
  2. 2.2 Topical Drugs CDMO Industry Drivers
  3. 2.3 Topical Drugs CDMO Industry Opportunities and Challenges
  4. 2.4 Topical Drugs CDMO Industry Restraints
3 Topical Drugs CDMO Market by Company
  1. 3.1 Global Topical Drugs CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Topical Drugs CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Topical Drugs CDMO Company Ranking (2024-2026)
  4. 3.4 Global Topical Drugs CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Topical Drugs CDMO Company Product Type and Application
  6. 3.6 Global Topical Drugs CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Topical Drugs CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Topical Drugs CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Topical Drugs CDMO Market by Type
  1. 4.1 Topical Drugs CDMO Type Introduction
  2. 4.1.1 Contract Development
  3. 4.1.2 Contract Manufacturing
  4. 4.2 Global Topical Drugs CDMO Sales Value by Type
  5. 4.2.1 Global Topical Drugs CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Topical Drugs CDMO Sales Value by Type (2021-2032)
  7. 4.2.3 Global Topical Drugs CDMO Sales Value Share by Type (2021-2032)
5 Topical Drugs CDMO Market by Application
  1. 5.1 Topical Drugs CDMO Application Introduction
  2. 5.1.1 Semi-Solid Formulations
  3. 5.1.2 Solid Formulations
  4. 5.1.3 Liquid Formulations
  5. 5.1.4 Others
  6. 5.2 Global Topical Drugs CDMO Sales Value by Application
  7. 5.2.1 Global Topical Drugs CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Topical Drugs CDMO Sales Value by Application (2021-2032)
  9. 5.2.3 Global Topical Drugs CDMO Sales Value Share by Application (2021-2032)
6 Topical Drugs CDMO Regional Value Analysis
  1. 6.1 Global Topical Drugs CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Topical Drugs CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Topical Drugs CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Topical Drugs CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Topical Drugs CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Topical Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Topical Drugs CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Topical Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Topical Drugs CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Topical Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Topical Drugs CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Topical Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Topical Drugs CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Topical Drugs CDMO Sales Value Share by Country, 2025 VS 2032
7 Topical Drugs CDMO Country-level Value Analysis
  1. 7.1 Global Topical Drugs CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Topical Drugs CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Topical Drugs CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Topical Drugs CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Topical Drugs CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Topical Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Topical Drugs CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Piramal Pharma Solutions
  2. 8.1.1 Piramal Pharma Solutions Company Information
  3. 8.1.2 Piramal Pharma Solutions Business Overview
  4. 8.1.3 Piramal Pharma Solutions Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio
  6. 8.1.5 Piramal Pharma Solutions Recent Developments
  7. 8.2 Pierre Fabre Group
  8. 8.2.1 Pierre Fabre Group Company Information
  9. 8.2.2 Pierre Fabre Group Business Overview
  10. 8.2.3 Pierre Fabre Group Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pierre Fabre Group Topical Drugs CDMO Product Portfolio
  12. 8.2.5 Pierre Fabre Group Recent Developments
  13. 8.3 PCI Pharma Services
  14. 8.3.1 PCI Pharma Services Company Information
  15. 8.3.2 PCI Pharma Services Business Overview
  16. 8.3.3 PCI Pharma Services Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 PCI Pharma Services Topical Drugs CDMO Product Portfolio
  18. 8.3.5 PCI Pharma Services Recent Developments
  19. 8.4 MedPharm Ltd.
  20. 8.4.1 MedPharm Ltd. Company Information
  21. 8.4.2 MedPharm Ltd. Business Overview
  22. 8.4.3 MedPharm Ltd. Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MedPharm Ltd. Topical Drugs CDMO Product Portfolio
  24. 8.4.5 MedPharm Ltd. Recent Developments
  25. 8.5 Lubrizol Life Science
  26. 8.5.1 Lubrizol Life Science Company Information
  27. 8.5.2 Lubrizol Life Science Business Overview
  28. 8.5.3 Lubrizol Life Science Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lubrizol Life Science Topical Drugs CDMO Product Portfolio
  30. 8.5.5 Lubrizol Life Science Recent Developments
  31. 8.6 DPT Laboratories LTD.
  32. 8.6.1 DPT Laboratories LTD. Company Information
  33. 8.6.2 DPT Laboratories LTD. Business Overview
  34. 8.6.3 DPT Laboratories LTD. Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio
  36. 8.6.5 DPT Laboratories LTD. Recent Developments
  37. 8.7 Contract Pharmaceuticals Limited
  38. 8.7.1 Contract Pharmaceuticals Limited Company Information
  39. 8.7.2 Contract Pharmaceuticals Limited Business Overview
  40. 8.7.3 Contract Pharmaceuticals Limited Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio
  42. 8.7.5 Contract Pharmaceuticals Limited Recent Developments
  43. 8.8 Cambrex Corporation
  44. 8.8.1 Cambrex Corporation Company Information
  45. 8.8.2 Cambrex Corporation Business Overview
  46. 8.8.3 Cambrex Corporation Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cambrex Corporation Topical Drugs CDMO Product Portfolio
  48. 8.8.5 Cambrex Corporation Recent Developments
  49. 8.9 Bora Pharmaceutical CDMO
  50. 8.9.1 Bora Pharmaceutical CDMO Company Information
  51. 8.9.2 Bora Pharmaceutical CDMO Business Overview
  52. 8.9.3 Bora Pharmaceutical CDMO Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio
  54. 8.9.5 Bora Pharmaceutical CDMO Recent Developments
  55. 8.10 Ascendia Pharmaceuticals
  56. 8.10.1 Ascendia Pharmaceuticals Company Information
  57. 8.10.2 Ascendia Pharmaceuticals Business Overview
  58. 8.10.3 Ascendia Pharmaceuticals Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio
  60. 8.10.5 Ascendia Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst